Caribou inks deal with MSK to make allogeneic therapies

By The Science Advisory Board staff writers

November 18, 2020 -- Memorial Sloan Kettering Cancer Center (MSK) has agreed to exclusively license its antibody fragments to CRISPR genome editing firm Caribou Biosciences to develop allogeneic cell therapies for cancer.

The agreement grants Caribou the right to its fully human anti-CD371 single-chain variable fragment (scFv) product. It also grants the company the right to intellectual property related to the field of allogeneic CD371-targeted cell therapies including chimeric antigen receptor (CAR)-T, CAR-natural killer (NK), or induced pluripotent stem cell (iPSC)-derived cell products. The antibody fragments will be used to create therapies for acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS).

The anti-CD371 scFvs were developed in a lab at MSK in collaboration with the Tri-Institutional Therapeutic Discovery Institute, a nonprofit drug discovery company wholly owned by MSK, Weill Cornell Medicine, and the Rockefeller University.

The financial terms of the agreement were not disclosed.

Precigen doses first patients with UltraCAR-T cells
Precigen said that the first patients in two phase I clinical trials have been treated with UltraCAR-T cells manufactured by its UltraPorator system.
Improving the safety of gene therapies 2 different ways
Two groups of researchers have developed unique approaches to overcome the limitations of delivery of gene editing therapeutics. In a pair of new papers,...
Intellia to advance CRISPR treatment for sickle cell
Intellia Therapeutics has received a grant from the Bill & Melinda Gates Foundation to research in vivo sickle cell disease treatments using its CRISPR/Cas9...
Caribou, MaxCyte enter CRISPR license agreement
Caribou Biosciences and MaxCyte have announced a clinical and commercial license agreement for the development of Carbiou's CAR-T cell therapy program.
CAR-T cell therapy research shows encouraging signs for mesothelioma patients
Every year, nearly 3,000 new cases of mesothelioma are diagnosed in the United States. While this is just a small percentage of overall cancer diagnoses,...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter